ArticleDiagnostics (Basel, Switzerland)2020
Identification of Key Biomarkers in Bladder Cancer: Evidence from a Bioinformatics Analysis.
Article in Diagnostics (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 35 citations in OpenAlex.
- Construction of a multimodal esophageal cancer prognostic model with screening of key genes and investigation of their biological functions.Discover oncology · 2025Article
- Tropomyosin Isoforms as Biomarkers for Urothelial Bladder Cancer: Promise and Challenges.Cureus · 2025Review
- Intervention of machine learning in bladder cancer research using multi-omics datasets: systematic review on biomarker identification.Discover oncology · 2025Review
- Integrative multi-omics and machine learning identify a robust signature for discriminating prognosis and therapeutic targets in bladder cancer.Journal of Cancer · 2025Article
- SurfR: Riding the wave of RNA-seq data with a comprehensive bioconductor package to identify surface protein-coding genes.Bioinformatics advances · 2025Article
- Review
- Advances in Genomic Data and Biomarkers: Revolutionizing NSCLC Diagnosis and Treatment.Cancers · 2023Review
- Identify Potential Urine Biomarkers for Bladder Cancer Prognosis Using NGS Data Analysis and Experimental Validation.Applied biochemistry and biotechnology · 2023Article
- Screening of immunotherapy-related genes in bladder cancer based on GEO datasets.Frontiers in oncology · 2023Article
- Six potential biomarkers for bladder cancer: key proteins in cell-cycle division and apoptosis pathways.Journal of the Egyptian National Cancer Institute · 2022Article
- Polygenic risk modeling of tumor stage and survival in bladder cancer.BioData mining · 2022Article
- Identification of hub genes in bladder cancer based on weighted gene co-expression network analysis from TCGA database.Cancer reports (Hoboken, N.J.) · 2022Article
- Article
- A New Approach to Drug Repurposing with Two-Stage Prediction, Machine Learning, and Unsupervised Clustering of Gene Expression.Omics : a journal of integrative biology · 2022Article
- The role ofFrontiers in surgery · 2022Article
- Construction of a Co-Expression Network for lncRNAs and mRNAs Related to Urothelial Carcinoma of the Bladder Progression.Frontiers in oncology · 2022Article
- CAR-T Cells in the Treatment of Urologic Neoplasms: Present and Future.Frontiers in oncology · 2022Review
- Prevention and Treatment of Side Effects of Immunotherapy for Bladder Cancer.Frontiers in oncology · 2022Review
- Tackling tumor microenvironment through epigenetic tools to improve cancer immunotherapy.Clinical epigenetics · 2021Review
- Implications of androgen receptor and FUS expression on tumor progression in urothelial carcinoma.Histology and histopathology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bladder cancer (BCa) is one of the most common malignancies and has a relatively poor outcome worldwide. However, the molecular mechanisms and processes of BCa development and progression remain poorly understood. Therefore, the present study aimed to identify candidate genes in the carcinogenesis and progression of BCa. Five GEO datasets and TCGA-BLCA datasets were analyzed by statistical software R, FUNRICH, Cytoscape, and online instruments to identify differentially expressed genes (DEGs), to construct protein‒protein interaction networks (PPIs) and perform functional enrichment analysis and survival analyses. In total, we found 418 DEGs. We found 14 hub genes, and gene ontology (GO) analysis revealed DEG enrichment in networks and pathways related to cell cycle and proliferation, but also in cell movement, receptor signaling, and viral carcinogenesis. Compared with noncancerous tissues, TPM1, CRYAB, and CASQ2 were significantly downregulated in BCa, and the other hub genes were significant upregulated. Furthermore, MAD2L1 and CASQ2 potentially play a pivotal role in lymph nodal metastasis. CRYAB and CASQ2 were both significantly correlated with overall survival (OS) and disease-free survival (DFS). The present study highlights an up to now unrecognized possible role of CASQ2 in cancer (BCa). Furthermore, CRYAB has never been described in BCa, but our study suggests that it may also be a candidate biomarker in BCa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.